JP2009539348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539348A5 JP2009539348A5 JP2009513297A JP2009513297A JP2009539348A5 JP 2009539348 A5 JP2009539348 A5 JP 2009539348A5 JP 2009513297 A JP2009513297 A JP 2009513297A JP 2009513297 A JP2009513297 A JP 2009513297A JP 2009539348 A5 JP2009539348 A5 JP 2009539348A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- cdr
- antibody
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims description 9
- 108090001123 antibodies Proteins 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 4
- 102000038129 antigens Human genes 0.000 claims description 4
- 108091007172 antigens Proteins 0.000 claims description 4
- 102100008989 IGHV1-2 Human genes 0.000 claims description 3
- 101710003461 IGHV1-2 Proteins 0.000 claims description 3
- 101710009640 IGKV1D-8 Proteins 0.000 claims description 3
- 101710024481 IGKV2-29 Proteins 0.000 claims description 3
- 101710009635 IGKV2D-26 Proteins 0.000 claims description 3
- 102100005978 IGKV3-20 Human genes 0.000 claims description 3
- 101710024987 IGKV3-20 Proteins 0.000 claims description 3
- 101710009651 IGKV3D-15 Proteins 0.000 claims description 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 3
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 3
- 102000020664 human HGF protein Human genes 0.000 claims 3
- 108091002800 human HGF protein Proteins 0.000 claims 3
- 102000005614 monoclonal antibodies Human genes 0.000 claims 3
- 108010045030 monoclonal antibodies Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 102000024070 binding proteins Human genes 0.000 description 3
- 108091007650 binding proteins Proteins 0.000 description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 230000001851 biosynthetic Effects 0.000 description 1
Description
別の態様として、本発明はヒトＨＧＦに結合する単離結合蛋白質を提供する。この結合蛋白質は、（ｉ）配列番号１７３（Ｈｕ２Ｂ８ Ｋｖ１−３９．１軽鎖可変領域）、配列番号１７９（Ｈｕ２Ｂ８ Ｋｖ３−１５．１軽鎖可変領域）、配列番号１９３（ＬＲ２Ｂ８ＬＣ軽鎖可変領域）及び配列番号１９９（ＬＲＭＲ２Ｂ８ＬＣ軽鎖可変領域）からなる群から選ばれる免疫グロブリン軽鎖可変領域、並びに（ｉｉ）配列番号１５９（Ｈｕ２Ｂ８ Ｈｖ１ｆ．１重鎖可変領域）、配列番号１６５（Ｈｕ２Ｂ８ Ｈｖ５ａ．１重鎖可変領域）、配列番号１６９（Ｈｕ２Ｂ８ Ｈｖ５−５１．１重鎖可変領域）、配列番号１８３（ＬＲ２Ｂ８ＨＣ重鎖可変領域）及び配列番号１８９（ＬＲＭＲ２Ｂ８ＨＣ重鎖可変領域）からなる群から選ばれる免疫グロブリン重鎖可変領域を含有する。上記結合蛋白質は、完全な状態の抗体又はその抗原結合性断片或いは生合成抗体結合部位とすることができる。
Claims (7)
- 配列番号１７７の免疫グロブリン軽鎖および配列番号１７１の免疫グロブリン重鎖を含む、ヒト肝細胞成長因子（ＨＧＦ）に結合する単離された抗体、または、その抗原結合フラグメント。
- モノクローナル抗体である、請求項１に記載の抗体。
- 以下：
（ｉ）配列番号１８の配列を含むＣＤＲＬ１、配列番号１９の配列を含むＣＤＲＬ２及び配列番号２０の配列を含むＣＤＲＬ３を含む、免疫グロブリン軽鎖可変領域；並びに
（ｉｉ）配列番号１５の配列を含むＣＤＲＨ１ 、配列番号２０３の配列を含むＣＤＲＨ２及び配列番号１７の配列を含むＣＤＲＨ３を含む、免疫グロブリン重鎖可変領域；
を含むヒト肝細胞成長因子（ＨＧＦ）に結合する単離された抗体、または、該抗体の抗原結合フラグメント。 - 前記ＣＤＲ配列が、ヒト又はヒト化フレームワーク配列間に挿入されている、請求項３に記載の抗体。
- 配列番号１７３のアミノ酸配列を含む免疫グロブリン軽鎖可変領域および配列番号１６９のアミノ酸配列を含む免疫グロブリン重鎖可変領域を含む、ヒト肝細胞成長因子（ＨＧＦ）に結合する単離された抗体、または、その抗原結合フラグメント。
- モノクローナル抗体である、請求項３に記載の抗体。
- モノクローナル抗体である、請求項５に記載の抗体。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81071406P | 2006-06-02 | 2006-06-02 | |
| US86046106P | 2006-11-21 | 2006-11-21 | |
| PCT/US2007/012950 WO2007143098A2 (en) | 2006-06-02 | 2007-06-01 | Hepatocyte growth factor (hgf) binding proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010167648A Division JP5528246B2 (ja) | 2006-06-02 | 2010-07-26 | 肝細胞成長因子（ｈｇｆ）結合蛋白質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009539348A JP2009539348A (ja) | 2009-11-19 |
| JP2009539348A5 true JP2009539348A5 (ja) | 2010-08-05 |
| JP4560582B2 JP4560582B2 (ja) | 2010-10-13 |
Family
ID=38802082
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009513297A Expired - Fee Related JP4560582B2 (ja) | 2006-06-02 | 2007-06-01 | 肝細胞成長因子（ｈｇｆ）結合蛋白質 |
| JP2010167648A Expired - Fee Related JP5528246B2 (ja) | 2006-06-02 | 2010-07-26 | 肝細胞成長因子（ｈｇｆ）結合蛋白質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010167648A Expired - Fee Related JP5528246B2 (ja) | 2006-06-02 | 2010-07-26 | 肝細胞成長因子（ｈｇｆ）結合蛋白質 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US7659378B2 (ja) |
| EP (2) | EP2029627B1 (ja) |
| JP (2) | JP4560582B2 (ja) |
| KR (1) | KR101196184B1 (ja) |
| AR (1) | AR061170A1 (ja) |
| AT (1) | ATE533787T1 (ja) |
| AU (1) | AU2007254853B2 (ja) |
| BR (1) | BRPI0712223A2 (ja) |
| CA (1) | CA2654019A1 (ja) |
| ES (1) | ES2378097T3 (ja) |
| HK (1) | HK1129394A1 (ja) |
| IL (2) | IL195038A0 (ja) |
| MX (1) | MX2008015138A (ja) |
| NO (1) | NO20085422L (ja) |
| NZ (1) | NZ573819A (ja) |
| WO (1) | WO2007143098A2 (ja) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007254853B2 (en) | 2006-06-02 | 2011-11-17 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding proteins |
| DK2027156T3 (da) * | 2006-06-02 | 2011-04-26 | Aveo Pharmaceuticals Inc | Hepatocytvækstfaktor (HGF)bindingsprotein |
| CA2691378A1 (en) | 2007-07-02 | 2009-01-08 | Oncomed Pharmaceuticals, Inc. | Antibody against human r-spondin (rspo) and use thereof for inhibition of beta-catenin signaling and treatment of cancer |
| US20090124022A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Antibodies that bind to mammalian ngal and uses thereof |
| US20090123946A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| US8846036B2 (en) | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| MX2010011955A (es) | 2008-04-29 | 2011-01-21 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| BRPI0912035A2 (pt) | 2008-05-29 | 2017-05-23 | Galaxy Biotech Llc | anticorpo monoclonal, composição farmacêutica, uso de uma composição farmacêutica, mab de camundongo na forma quimérica ou humanizada, e, anticorpo humanizado |
| MX2010013239A (es) * | 2008-06-03 | 2011-02-24 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| NZ589436A (en) * | 2008-06-03 | 2012-12-21 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2010002862A2 (en) * | 2008-07-01 | 2010-01-07 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| CN102149825B (zh) | 2008-07-08 | 2015-07-22 | Abbvie公司 | 前列腺素e2双重可变结构域免疫球蛋白及其用途 |
| PT2305300E (pt) | 2008-07-10 | 2016-06-16 | Toray Industries | Composição farmacêutica para o tratamento e prevenção do cancro |
| EP2842573B1 (en) | 2008-11-07 | 2017-09-27 | Galaxy Biotech, LLC | Monoclonal antibodies to Fibroblast Growth Factor receptor 2 |
| SG2014006878A (en) * | 2008-11-12 | 2014-04-28 | Merck Sharp & Dohme | ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION |
| US20120052064A1 (en) | 2009-04-17 | 2012-03-01 | Yuuki Ito | Anti-hgf antibody combinational cancer therapies |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| PE20121530A1 (es) * | 2009-09-01 | 2012-12-22 | Abbvie Inc | Inmunoglobulinas con dominio variable dual |
| JP2013507928A (ja) | 2009-10-15 | 2013-03-07 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| WO2012018790A2 (en) | 2010-08-03 | 2012-02-09 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| CN103260639A (zh) | 2010-08-26 | 2013-08-21 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| MX2013005847A (es) * | 2010-11-24 | 2013-12-12 | Glaxo Group Ltd | Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf. |
| KR20140048276A (ko) | 2011-07-15 | 2014-04-23 | 온코메드 파마슈티칼스, 인크. | Rspo 결합제 및 이의 용도 |
| WO2013078223A1 (en) * | 2011-11-23 | 2013-05-30 | Children's Hospital & Research Center Oakland | Anti-factor h binding protein antibodies and methods of use thereof |
| BR112014015851A2 (pt) | 2011-12-30 | 2019-09-24 | Abbvie Inc | proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17 |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| MX2015000565A (es) | 2012-07-13 | 2015-04-10 | Oncomed Pharm Inc | Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos. |
| KR20210111353A (ko) | 2012-11-01 | 2021-09-10 | 애브비 인코포레이티드 | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 |
| KR20150140685A (ko) * | 2013-03-14 | 2015-12-16 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | Hgf에 대한 항체 및 이를 포함하는 조성물 |
| US9481725B2 (en) | 2013-03-14 | 2016-11-01 | Alderbio Holdings, Llc | Antibodies to HGF and compositions containing |
| MX2015013166A (es) | 2013-03-15 | 2015-12-11 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. |
| WO2015031578A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Hgf assay |
| CN107002119A (zh) | 2014-03-24 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联 |
| JP2017526356A (ja) * | 2014-08-15 | 2017-09-14 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｒｓｐｏ１結合剤およびその使用 |
| EP3193935A4 (en) | 2014-09-16 | 2018-03-21 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| US10550187B2 (en) | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
| US10316094B2 (en) | 2014-10-24 | 2019-06-11 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| WO2016205566A1 (en) * | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| KR102364249B1 (ko) | 2016-03-28 | 2022-02-17 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 항-ryk 항체 및 이의 사용 방법 |
| NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| US11149094B2 (en) | 2017-06-05 | 2021-10-19 | Janssen Biotech, Inc. | Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations |
| EP3638299A4 (en) * | 2017-06-15 | 2021-03-31 | Memorial Sloan-Kettering Cancer Center | ANTI-L1-CAM ANTIBODIES AND USES THEREOF |
| KR102443358B1 (ko) | 2017-12-06 | 2022-09-14 | 어비디티 바이오사이언시스 인크. | 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법 |
| US11155638B2 (en) | 2018-05-08 | 2021-10-26 | Rhode Island Hospital | Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications |
| CN114008079A (zh) * | 2019-03-20 | 2022-02-01 | 贾夫林肿瘤学公司 | 抗adam12抗体和嵌合抗原受体以及包含其的组合物和方法 |
| EP4013869A1 (en) | 2019-08-12 | 2022-06-22 | InteRNA Technologies B.V. | New treatments involving mirna-193a |
| WO2021170786A1 (en) | 2020-02-28 | 2021-09-02 | Interna Technologies B.V. | miRNA-193a FOR PROMOTING IMMUNOGENIC CELL DEATH |
| WO2021195469A1 (en) * | 2020-03-27 | 2021-09-30 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
| DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
| US6498144B1 (en) * | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
| US5707624A (en) * | 1994-06-03 | 1998-01-13 | The Regents Of The University Of Michigan | Treatment of Kaposi's sarcoma by inhibition of scatter factor |
| JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク． | 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
| US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
| AU1598801A (en) * | 1999-11-09 | 2001-06-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | HGF-SF monoclonal antibody combinations |
| MXPA05000511A (es) * | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
| US7220410B2 (en) * | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
| PL1648998T3 (pl) | 2003-07-18 | 2015-03-31 | Amgen Inc | Specyficzne czynniki wiążące czynnik wzrostu hepatocytów |
| KR100556660B1 (ko) | 2003-11-11 | 2006-03-10 | 국립암센터 | Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체 |
| BRPI0611009A2 (pt) * | 2005-06-02 | 2010-08-10 | Galaxy Biotech Llc | usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização |
| AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
| DK2027156T3 (da) | 2006-06-02 | 2011-04-26 | Aveo Pharmaceuticals Inc | Hepatocytvækstfaktor (HGF)bindingsprotein |
| AU2007254853B2 (en) | 2006-06-02 | 2011-11-17 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding proteins |
| KR100829972B1 (ko) * | 2006-07-14 | 2008-05-16 | 재단법인서울대학교산학협력재단 | 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법 |
-
2007
- 2007-06-01 AU AU2007254853A patent/AU2007254853B2/en not_active Ceased
- 2007-06-01 NZ NZ573819A patent/NZ573819A/en not_active IP Right Cessation
- 2007-06-01 WO PCT/US2007/012950 patent/WO2007143098A2/en active Application Filing
- 2007-06-01 JP JP2009513297A patent/JP4560582B2/ja not_active Expired - Fee Related
- 2007-06-01 US US11/757,094 patent/US7659378B2/en active Active
- 2007-06-01 ES ES07795607T patent/ES2378097T3/es active Active
- 2007-06-01 AR ARP070102388A patent/AR061170A1/es not_active Application Discontinuation
- 2007-06-01 BR BRPI0712223-3A patent/BRPI0712223A2/pt not_active IP Right Cessation
- 2007-06-01 KR KR1020087032082A patent/KR101196184B1/ko not_active IP Right Cessation
- 2007-06-01 AT AT07795607T patent/ATE533787T1/de active
- 2007-06-01 MX MX2008015138A patent/MX2008015138A/es active IP Right Grant
- 2007-06-01 CA CA002654019A patent/CA2654019A1/en not_active Abandoned
- 2007-06-01 EP EP07795607A patent/EP2029627B1/en not_active Not-in-force
- 2007-06-01 EP EP11159440A patent/EP2380908A1/en not_active Withdrawn
-
2008
- 2008-11-02 IL IL195038A patent/IL195038A0/en unknown
- 2008-12-30 NO NO20085422A patent/NO20085422L/no not_active Application Discontinuation
-
2009
- 2009-08-13 HK HK09107469.8A patent/HK1129394A1/xx not_active IP Right Cessation
- 2009-12-07 US US12/632,758 patent/US7935502B2/en not_active Expired - Fee Related
-
2010
- 2010-07-26 JP JP2010167648A patent/JP5528246B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-18 US US13/051,474 patent/US8268315B2/en not_active Expired - Fee Related
-
2012
- 2012-05-08 IL IL219655A patent/IL219655A0/en unknown
- 2012-08-20 US US13/589,652 patent/US8575318B2/en not_active Expired - Fee Related
-
2013
- 2013-09-27 US US14/039,912 patent/US20140178934A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539348A5 (ja) | ||
| JP2009225799A5 (ja) | ||
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| JP2017114866A5 (ja) | ||
| JP2010246565A5 (ja) | ||
| JP2013523166A5 (ja) | ||
| NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| WO2006071441A3 (en) | Antibodies directed to gpnmb and uses thereof | |
| WO2006039258A3 (en) | Human antibodies against parathyroid hormone | |
| JP2018504105A5 (ja) | ||
| WO2006055809A3 (en) | Antibodies against vascular endothelial growth factor receptor-1 | |
| RU2531523C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| WO2006113643A3 (en) | High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies | |
| JP2010526028A5 (ja) | ||
| JP2010511388A5 (ja) | ||
| WO2006130458A3 (en) | Antibodies directed to cd20 and uses thereof | |
| IL173323A0 (en) | Antibodies directed to parathyroid hormone (pth) and uses thereof | |
| JP2010535205A5 (ja) | ||
| JP2017512759A5 (ja) | ||
| NZ585622A (en) | Hepatitis c virus antibodies | |
| NO20074867L (no) | Antistoffer mot CCR5 og anvendelser derav | |
| WO2005069970A3 (en) | Antibody specificity transfer using minimal essential binding determinants | |
| JP2013506428A5 (ja) | ||
| WO2007070432A3 (en) | Binding proteins specific for insulin-like growth factors and uses thereof | |
| NZ601342A (en) | Antibodies that bind il-4 and/or il-13 and their uses |